The Effects of Bradykinin B1 Receptor Antagonism on the Myocardial and Vascular Consequences of Hypertension in SHR Rats

Laszlo Deres1,2, Krisztian Eros1,2, Orsolya Horvath1,2, Noemi Bencze1,2, Csongor Cseko3, Sandor Farkas3, Tamás Habon4, Kalman Toth2,4 and Robert Halmosi2,4*

1 Medical School, University of Pécs, Pécs, Hungary, 2 Szentagothai Research Centre, University of Pécs, Pécs, Hungary, 3 Gedeon Richter Plc., Budapest, Hungary, 4 1st Department of Medicine, Clinical Centre, University of Pécs, Pécs, Hungary

It is known that non-steroidal anti-inflammatory drugs increase cardiovascular (CV) morbidity and mortality. In this study, we examined whether a novel anti-inflammatory drug, bradykinin B1 receptor antagonist (FGY-1153) treatment could influence the development of hypertensive organ damages in spontaneously hypertensive rats (SHR). SHRs were treated with low (FGY-120) or high dose FGY-1153 (FGY-400) and with placebo (Control) for 26 weeks. Wistar–Kyoto rats were used as aged-matched, normotensive controls (WKY). Body weight, food consumption and blood pressure were measured regularly. Echocardiography was performed at the beginning and at the end of the study. Light and electron microscopic analysis of heart and great vessels were performed, and the extent of fibrotic areas was measured. The phosphorylation state of prosurvival Akt-1/glycogen synthase kinase (GSK)-3β pathway and the activation of signaling factors playing part in the fibrotic processes – mitogen activated protein kinases (MAPKs), and TGF-β/Smad2 – were monitored using Western-blot. Body weight and food consumption as well as the elevated blood pressure in SHRs was not influenced by FGY-1153 treatment. However, both doses of FGY-1153 treatment decreased left ventricular (LV) hypertrophy and diastolic dysfunction in hypertensive animals. Moreover systolic LV function was also preserved in FGY-120 group. Increased intima-media thickness and interstitial fibrosis were not significantly diminished in great vessels. FGY-1153 treatment inhibited the expression of TGFβ and the phosphorylation of SMAD2 in the heart. Our results suggest that the tested novel anti-inflammatory compound has no deleterious effect on CV system, moreover it exerts moderate protective effect against the development of hypertensive cardiopathy.

Keywords: hypertensive target organ damages, bradykinin B1 receptor antagonism, NSAIDs, cardiovascular remodeling, echocardiography, spontaneously hypertensive rats
INTRODUCTION

It is well known, that the worldwide most commonly prescribed pain relievers, the NSAIDs can significantly increase cardiovascular morbidity and mortality (Patrono and Baigent, 2014). Only the low dose aspirin treatment – without significant painkiller moiety – has positive effect on survival (Patrono et al., 2005). This unfavorable phenomenon is partly caused by the increase in atherothrombotic events (Garcia Rodriguez et al., 2008; McGettigan and Henry, 2011), however, the other major cause is the increase in mortality due to heart failure (Garcia Rodriguez and Hernandez-Diaz, 2003). Therefore there is an unmet medical need to develop novel and safer anti-inflammatory compounds.

The kallikrein–kinin system is one of the multiple systems which play a role in initiation, propagation and maintenance of inflammation and pain (Moreau et al., 2005). Kinins stimulate the synthesis and release of nitric oxide, cytokines, arachidonic acid, leukotrienes as well as chemotactic factors (Lerner et al., 1989; Tiffany and Burch, 1989; Sato et al., 1996). Primary kinins (e.g., bradykinin) act predominantly on constitutively expressed (brady)kinin B2 receptors, however, secondary kinins with longer half-life (e.g., des-arginin bradykinin) bind mainly to B1 receptors (Farkas and Eles, 2011). Bradykinin B1 receptors are expressed at a very low level in healthy tissues, but undergo massive induction due to tissue injury or inflammation. Therefore the inhibition of these receptors can be effective in the relief of chronic pain and inflammation. Moreover the pharmacological inhibition of bradykinin B1 receptors theoretically seems to be safe because of the previously mentioned features (Marceau and Bachvarov, 1998).

Actually in several works beneficial cardiac effects of bradykinin B1 receptor antagonism were showed. In KO animals and using pharmacological blockade of kinin B1 receptors, both *ex vivo* and *in vivo* the size of myocardial or cerebral infarct size decreased markedly (Lagneux et al., 2002; Yin et al., 2007; Austinat et al., 2009). An other workgroup proved, that in a diabetic cardiomyopathy model the systolic and diastolic left ventricular (LV) function was better in bradykinin B1 KO animals than in wild type ones (Westermann et al., 2009).

So far there is no data in the literature regarding the effect of kinin B1 receptor antagonism in chronic elevated blood pressure. Hypertension is one of the most important risk factor of cardio- and cerebrovascular diseases and based on population-attributable risk, hypertension has the greatest impact on the development of heart failure (Lloyd-Jones, 2001). SHR is a widely accepted and used animal model to examine the development of hypertension-induced target organ damages (Trippodo and Frohlich, 1981). According to the literature, the beginning of the hypertension is at the age of 6 to 8 weeks, which, by the age of 30 weeks leads to significant target organ damages (Kukubo et al., 2005).

In this work we aimed to evaluate the effects of a new type anti-inflammatory drug, a bradykinin B1 receptor antagonist (FGY-1153) on the development of hypertensive target organ damages in spontaneously hypertensive rats (SHR).

MATERIALS AND METHODS

Experimental Protocol

Forty-five male SHR (Charles River Laboratories, Budapest, Hungary) were used. The animals were 8 weeks old on arrival and weighed approximately 250–270 g. The study was started after an acclimatization period of 3 weeks. SHRs were randomly divided into three groups: Control group (*n* = 15), FGY120 group (*n* = 15) and FGY400 group (*n* = 15). The animals of FGY120 received test diet mixed with FGY-1153 at 120 ppm concentration (estimated to yield a dose level of approximately 6 mg/kg/day). The animals of FGY400 group received test diet mixed with FGY-1153 at 400 ppm concentration (estimated to a dose level of approximately 20 mg/kg/day). The special rat chow was purchased from Soniff Spezialitäten GmbH, Germany. The active ingredient (FGY1153) was developed by Richter Gedeon Plc., Hungary. The animals of the Control group received control diet (0 ppm concentration). The treatment with FGY-1153 started at the age of about 11-weeks. During the whole duration of the study (26 weeks) animals were treated orally, using standard rat chow containing FGY-1153 (in 120 or 400 ppm), or control rat diet. The rat chow was available to the animals *ad libitum*. SHR rats were observed daily, to achieve a description of normal activity, responsiveness to manipulation, weight, respiration, and general aspect (López et al., 2007).

Ten male Wistar-Kyoto age-matched rats (Harlan Laboratories S.R.L., San Pietro al Natisone, Italy) were used as a normotensive control group (WKY group). The animals of WKY group received control diet (0 ppm concentration). The animals were 32 weeks old on arrival and weighed approximately 380–420 g. After an acclimatization period of 2 weeks they were sacrificed.

Investigations and Measurements

Food Consumption and Body Weight

During the last 2 weeks of the acclimatization period, all animals received Control test diet (0 ppm concentration) for adaptation. The quantity of food consumed by each cage of animals was measured and recorded daily during the adaptation period. The quantity of food consumed by each cage of animals was measured and recorded once weekly during the treatment period (except for age-matched WKY group).

Body weights were measured and recorded once weekly during the acclimatization and treatment periods and on the day of necropsy (except for age-matched WKY group).

Measurement of Blood Pressure

Non-invasive blood pressure measurements were performed on each animal on three occasions at Weeks 0, 13, and 26 of the treatment period. Blood pressure measurements were performed by a non-invasive tail-cuff method as described earlier (Kubota et al., 2006; Magyar et al., 2014). Blood pressure was measured by Hatteras SC1000 Blood Pressure Analysis System with rat species platform (Panlab, Harvard Apparatus; LE5001; except for age-matched WKY group).
paraformaldehyde solution (4%) for 1 day. Five processing were fixed immediately after excision in buffered Heart, carotid arteries and aortic segments excised for histological Investigation of Vascular and Cardiac Remodeling by: 100 and LVIDs), E/E’ ratio and the thickness of septum and systolic volume (LVESV), LV inside dimensions (LVIDd functions were measured from short- and long-axis views at the mid-papillary level by a VEVO 770 high-resolution ultrasound imaging system (VisualSonic, Toronto, ON, Canada) – equipped with a 25 MHz transducer. LV ejection fraction (EF), LV end-diastolic volume (LVEDV), LV end-systolic volume (LVESV), LV inside dimensions (LVIDd and LVIDs), E/E’ ratio and the thickness of septum and posterior wall (PW) were determined. EF (%) was calculated by: 100 × [(LVEDV – LVESV)/LVEDV]; relative wall thickness (RWT) was calculated by: (PW thickness + interventricular septal thickness)/LVIDd.

Investigation of Vascular and Cardiac Remodeling With Histology and Immunohistochemistry Heart, carotid arteries and aortic segments excised for histological processing were fixed immediately after excision in buffered paraformaldehyde solution (4%) for 1 day. Five μm thick sections were cut. Slices were stained with Masson’s trichrome staining to detect the interstitial fibrosis as described earlier (Deres et al., 2014; Magyar et al., 2014).

The intima-media thickness was measured on cross sections of histological preparations from great arteries with Mirax Viewer software (version: 1.12.22.0). For assessment of cardiac fibrosis, five samples were taken from all cross-sectioned cardiac preparations at constant magnification from separate, continuous territories excluding perivascular, sub-endo- and sub-pericardial areas. Different stainings were discriminated by Color deconvolution plugin for ImageJ with built-in color vectors for Masson’s trichrome. After autothresholding, the area fraction of aniline-blue staining was measured in each sample and ANOVA analysis was performed.

For evaluation of vascular fibrosis, five different areas (ROIs) from the territories of the tunica media layers of aorta and carotid arteries were selected, where measurements have been made. Different stainings were discriminated by Color deconvolution plugin for ImageJ with built-in color vectors for Masson’s trichrome. After autothresholding, the area fraction of aniline-blue staining has been measured in each predefined ROIs. On carotis data Square root transformation has been made.

All histological samples were examined by an investigator in a blinded fashion.

Evaluation of Cardiac and Vascular Remodeling With Electron Microscopy Electron microscopic examinations were performed on hearts and great vessels from the treated and control SHR animals. The fixative was supplemented with 1% glutaraldehyde. After washing, samples were stained with 1% OsO4 in PB, dehydrated through ascending ethanol series and embedded in Durcupan ACM resin. Sections were cut, counterstained with Reynold’s lead citrate, and examined and photographed in a JEOL 1200 EX electron microscope. All histological samples were examined by an investigator in a blinded fashion.

Western Blot Analysis on Heart and Great Vessels Heart samples, carotid arteries and aortic segments were homogenized in ice-cold 50 mM Tris-buffer, pH 8.0 (containing Protease and Phosphatase Inhibitor Cocktail 1:1000, Sigma Aldrich – P83840, P5726 and 50 mM sodium vanadate) and harvested in 2× concentrated SDS-polyacrylamide gel electrophoresis sample buffer. Proteins were separated on 10 or 12% SDS-polyacrylamide electrophoresis gel and transferred to nitrocellulose membranes. After blocking (2 h with 3% non-fat milk in Tris-buffered saline), membranes were probed overnight at 4°C with antibodies recognizing the following antigens: anti-N-terminal domain of beta-actin (1:10,000; Cell Signaling Technology, 3700S), extracellular signal regulated kinase (ERK 1/2; 1:1000; Cell Signaling Technology, 9170S) and phospho-specific ERK 1/2 Thr180/Tyr183 (1:1000; Cell Signaling Technology, 4370S), c-Jun N-terminal kinase (JNK; 1:1000; Cell Signaling Technology, 3708S) and phospho-specific JNK Thr183/Tyr185 (1:1000; Cell Signaling Technology, 9255S ), TGF-beta (1:1000; Cell Signaling Technology, 3711S), SMAD2 (1:1000; Invitrogen, 436500) and phospho-specific SMAD2 Ser465/467 (1:1000; Invitrogen, MA5-15122), p38 MAPK (1:000; Invitrogen, AOH1202) phospho-specific p38-MAPK Thr180-Gly-Tyr182 (1:1000; Invitrogen, MA5-15177), Akt (1:1000; Cell Signaling Technology, 9272S) and phospho-specific Akt Ser473 (1:1000; Cell Signaling Technology, 9018S), GSK-3-beta (1:000; Signaling Technology, 9155S) and phospho-specific GSK-3-beta Ser21 (1:1000; Cell Signaling Technology, 9232S). Membranes were washed six times for 5 min in Tris-buffered saline (pH 7.5) containing 0.2% Tween (TBST) before addition of goat anti-rabbit horseradish peroxidase-conjugated secondary antibody (1:3000 dilution). The antibody– antigen complexes were visualized by means of enhanced chemiluminescence. After scanning, results were quantified by NIH Image J program.

Blood Sampling To assess drug plasma exposures, blood samples were collected from the rats by direct cardiac puncture on the last day of the study just before necropsy between 08.20 am and 12.20 pm. The blood samples were drawn into either heparinized tubes or Lavender Vacutainer tubes containing EDTA. The blood samples were centrifuged at 1600 C to separate plasma. Supernatants were collected and kept at −70°C.

Statistical Analysis The data are expressed as mean ± SEM. For comparison of WKY and Control groups, independent sample’s t-test (2-tailed) was applied. Control and Treatment groups were analyzed...
using one-way ANOVA (SPSS for Windows 20.0). For post hoc comparison Dunnett’s test (2-tailed) was chosen. In cases of inhomogeneous group variances Welch correction was applied followed by Dunnett T3 post hoc test. On GCL cell number data Kruskal–Wallis test was conducted, due to extreme non-normal distribution of the FGY400 group. Values of \( p < 0.05 \) were considered statistically significant. All individual data are tabulated in the Appendix.

**RESULTS**

**Effect of FGY-1153 on Body Weight and Food Consumption**

Body weights were measured and recorded once weekly during the treatment period. There were no significant differences between the three hypertensive groups neither at the beginning nor at the end of treatment period (Control: 362.4 ± 4.4 g, FGY120: 366.8 ± 3.3 g, FGY400: 369.1 ± 5.8 g) (Figure 1). The quantity of food consumed by each cage of animals was measured and recorded once weekly during the treatment period. There were no overt differences between the food consumptions of the three groups throughout the study (Figure 1 and Supplementary Tables S1–S6).

**FGY-1153 Dose Calculation and Drug Plasma Concentrations Detected**

The weekly calculated dose (calculation based upon: food consumption, FGY-1153 concentration in rat chow, body weight) of test substance was 6.32 ± 0.14 (ranged from 5.51 ± 0.47 to 7.76 ± 0.14) mg/kg/day in the FGY120 group and 20.9 ± 0.59 (ranged from 16.6 ± 0.4 to 28.0 ± 0.3) mg/kg/day in the FGY400 group (Supplementary Tables S7, S8, \( n = 15 \)).

Plasma concentrations measured from the rats of the FGY120 and FGY400 groups are presented in Supplementary Table S9.

**Effect of FGY-1153 on Blood Pressure**

At the beginning of the study there was no significant difference between the systolic arterial blood pressure of the three hypertensive groups (Control: 178.73 ± 3.25 mmHg, FGY120 group: 172.47 ± 3.81 mmHg, FGY400 group: 174.53 ± 2.30 mmHg, \( p = 0.374 \)). Systolic arterial blood pressure values did not differ significantly between the groups both at Week 13 (Control: 215.93 ± 6.11 mmHg, FGY120 group: 212.73 ± 5.68 mmHg, FGY400 group: 228.80 ± 4.48 mmHg, \( p = 0.096 \)) and at Week 26 (Control: 256.36 ± 8.04 mmHg, FGY120 group: 256.80 ± 7.69 mmHg, FGY400 group: 275.33 ± 3.07 mmHg, \( p = 0.078; \ n = 15 \)).

Nevertheless, a non-significant trend of higher blood pressure in the FGY400 group was apparent (Supplementary Table S10).

**Effect of FGY-1153 on Echocardiographic Parameters**

Compared to the parameters measured at the beginning of the study, the septum and PW thicknesses increased in all hypertensive groups during the treatment period (\( p < 0.01 \)). However, treatment with both low dose and high dose FGY-1153 significantly attenuated the hypertrophy of septum and PW (\( p < 0.01 \) and \( p < 0.05 \), respectively vs. Control).

LVIDs and LVIDd were also increased in all SHR groups during the study, but the elevation of these parameters were significantly attenuated in the FGY120 group (\( p < 0.05 \)), while not in the FGY400 group. Left ventricular systolic function – expressed as EF% – showed a decreasing tendency in both the Control group and the FGY400 group by the end of the study compared to the initial parameters (Table 1). In comparison with the Control group, these changes were significantly attenuated in the FGY120 group (\( p < 0.05 \) vs. Control), indicating that the low dose FGY-1153 treatment prevented the hypertension induced decrease in systolic left ventricular function. The E/E' ratio showed an increasing tendency during the study in the Control group, while this parameter was significantly decreased in both the FGY120 and FGY400 groups (\( p < 0.05 \) vs. Control) (Table 1 and Figure 2).

**Effect of FGY-1153 on the Interstitial Fibrosis of Heart and Great Vessels**

Analysis of interstitial fibrosis in SHR heart samples revealed no statistically significant difference between Control and Treatment groups (FGY120 and 400). The collagen content in WKY hearts, however, was significantly lower (\( p < 0.05 \)) compared to the Control group (Mean area fractions ± SEM: WKY: 0.390 ± 0.021; Control: 0.657 ± 0.069; FGY120: 0.636 ± 0.088; FGY400: 0.582 ± 0.041; \( n = 4 \)) (Figure 3).

In carotid arteries and aortas a statistically non-significant increase of vascular collagen could be observed in Control group compared to WKY. No significant differences could be found between Control, FGY120 and FGY400 groups (Mean area fractions ± SEM: Aorta: WKY: 1.084 ± 0.112 (\( p = 0.536 \) vs. Control); Control: 1.378 ± 0.414; FGY120: 1.239 ± 0.526; FGY400: 1.458 ± 0.324, (\( p = 0.936 \); \( n = 4 \))). In carotid arteries a statistically non-significant decrease of vascular collagen could be observed in treated groups: WKY: 4.860 ± 0.532 (\( p = 0.229 \) vs. Control); Control: 5.994 ± 0.660; FGY120: 5.745 ± 1.465; FGY400: 5.158 ± 1.097; (\( p = 0.866, \ n = 4 \) data not shown).

**Effect of FGY-1153 on the Intima-Media Thickness of Great Vessels**

The IMT of carotid arteries was the lowest in the normotensive WKY group, (Figures 4A,B,E) (\( p < 0.05 \) vs. Control \( n = 3 \)). Chronic hypertension caused a marked increase of IMT in the Control group. In comparison with the Control group (Figure 3B), the intima-media thickness of carotid vessels was slightly decreased in both the FGY120 and FGY400 groups (Figures 4C,D). However, the alterations were not statistically significant (\( p = 0.149, \ n = 4 \)).
Effect of FGY-1153 on the Ultrastructural Changes in the Myocardium and Great Vessels

Electron Microscopic Studies of the Myocardium

Transmission electron microscopic analysis of capillary endothelium in the myocardium (Supplementary Figures S1, S2) showed normal structure in all groups. The morphology of Eberth’ lines (not shown) and sarcomere units was also normal in both the Control and FGY-1153 treated groups (Supplementary Figures S1D–F). The nuclei of cardiomyocytes in the Control rats predominantly display euchromatin with minor membrane-associated marginal heterochromatin (Figure 5A). In contrast, in the other two groups cell nuclei were pale and displayed higher amount of membrane-associated marginal chromatin suggesting differences in the activity of transcription (Figures 5B,C). In the cytoplasm glycogen (Figure 5 and Supplementary Figures S1, S2 arrow heads) and lipid droplets (not shown) could be seen in all groups, however, the amount of glycogen was...
Electron Microscopic Studies of the Walls of Aortas and Carotid Arteries

The ultrastructure of the wall of normotensive aorta (not shown) and carotid arteries is characterized by endothelial cells lying almost directly on the internal elastic lamina (Supplementary Figure S3). The surface of the endothelial monolayer is smooth, the cells have very thin cytoplasm and an elongated nucleus which is oriented parallel to the internal elastic lamina. The subendothelial space is narrow, the internal elastic lamina is rarely interrupted. In the tunica...
Deres et al. Bradykinin B1-Receptor Antagonism and Hypertension

FIGURE 4 | Masson's trichrome staining of carotid vessels. IMT was the lowest in the WKY group (A). In comparison with the Control group (B), the intima-media thickness of carotid vessels was slightly decreased in both the FGY120 (C) and FGY400 groups (D), (n = 4). The alterations were not significant. Effect of FGY-1153 treatment on intima-media thickness of carotid vessels (E). IMT, intima-media thickness (*p < 0.05 vs. Control group (n = 3).

FIGURE 5 | Ultrastructural analysis of the cardiomyocytes in Control (A,D), FGY120 (B,E), and FGY400 (C,F) group. Sarcoplasm (sp), Muscle fibers (*), Mitochondria (m), Nuclei (nu), Glycogen (arrow heads), (n = 5 from each group, 3–5 block from each animal).

intima the cellular elements (fibroblasts, smooth muscle cells) are arranged between the layers of internal elastic lamina (Supplementary Figure S3).

In the carotid arteries (Figure 6) and also in the aorta (data not shown) of the SHR groups the wall structure was pathologic. The nuclei of smooth muscle cells in the intimal layer were lobular and showed signs of activation. The activated smooth muscle cells were involved in the synthesis of the components of fibers, which was confirmed by the presence of collagen and elastic fibers around them (Figure 6). Expanding smooth muscle cells sporadically broke through the internal elastic lamina (Figures 6C,E,F), resulting in the appearance of collagen and cellular elements in the subendothelial space. Accumulation of connective tissue and cellular elements in the subendothelial space can exert tension to the endothelial monolayer, so the endothelial cells became distorted, their cytoplasm was lateralized and in some places became thinner. Presumably the endothelial permeability increased due to cell distortion,
which contributed to subendothelial space expansion and further endothelial erosion.

Additional sign of tension-distorted endothelial cells is the altered orientation of their nuclei, which became rounded and protruded into the lumen, so the surface of the endothelial monolayer became rough (Figures 6A,B,E).

Rearrangement of tunica media layers could be seen, as a consequence of hypertension-induced smooth muscle cell activation and collagen synthesis. In the walls of carotid arteries more intensive collagen synthesis was seen compared to aortic walls. We could not see any significant differences between the control group and the treated groups (FGY120 and FGY 400) (Figure 6) \((n = 5\) from each group, 3–5 block from each animal).

**Effect of FGY-1153 on the TGFβ/SMAD2 Signaling Pathway in Heart and Great Vessels**

**Western Blot Analysis of Heart Samples**

Western blot analysis showed that both TGFβ and SMAD2 phosphorylation levels were significantly lower in WKY animals compared to the Control group. FGY-1153 treatment inhibited the cardiac expression of TGFβ and the phosphorylation of the SMAD2 protein in the FGY120 group, however, the high dose treatment had no significant effect on the phosphorylation of SMAD2 in the FGY400 group. Actin is shown as loading control. Representative immunoblots from four experiments and densitometric evaluation are demonstrated (Figure 7).

**Western Blot Analysis of Carotid Samples**

Western blot analysis showed that both TGFβ expression and SMAD2 phosphorylation levels were significantly higher in Control group relative to WKY. Both low and high dose FGY-1153 treatment significantly inhibited the expression of TGFβ. The phosphorylation of the SMAD2 protein was significantly decreased in both the FGY120 and in FGY400 groups in carotid tissues. Actin is shown as loading control. Representative immunoblots from four experiments and densitometric evaluation are demonstrated (Figure 8).

**Effect of FGY-1153 on the Phosphorylation of MAPK Signaling Cascade in Heart and Great Vessels**

**Western Blot Analysis of Heart Samples**

Western blot analysis showed significantly lower ERK1/2 phosphorylation level in WKY, relative to the Control group (Figure 9). FGY-1153 treatment significantly inhibited ERK1/2 phosphorylation in both FGY120 and in FGY400 hearts. However, it had no statistically significant effect on the phosphorylation of p38-MAPK and JNK proteins (data not shown).

**Western Blot Analysis of Carotid Samples**

Phosphorylation level of JNK was significantly higher in the Control relative to the WKY group. Western blot analysis showed that low dose FGY-1153 treatment had no significant effect on phosphorylation of p38-MAPK and JNK proteins, but elevated the phosphorylation level of ERK1/2 protein. High

---

**FIGURE 7** The effect of FGY-1153 on the TGFβ/SMAD2 signaling pathway in heart samples. Data are presented as mean ± S.E.M. Data were analyzed by independent samples t-test between WKY and Control groups. Comparisons of Control and Treatment groups were made by one-way ANOVA followed by Dunnett’s post hoc test. \(* p < 0.05, \** p < 0.01\) vs. Control, \(n = 4\).

---

**FIGURE 8** The effect of FGY-1153 on the TGFβ/SMAD2 signaling pathway in carotid samples. Data are presented as mean ± S.E.M. Data were analyzed by independent samples t-test between WKY and Control groups. Comparisons of Control and Treatment groups were made by one-way ANOVA followed by Dunnett’s post hoc test. \(* p < 0.05, \** p < 0.01\) vs. Control, \(n = 4\).
FIGURE 8 | The effect of FGY-1153 on the TGFβ/SMAD2 signaling pathway in the carotid arteries. Data are presented as mean ± S.E.M. Data were analyzed by independent samples t-test between WKY and Control groups. Comparisons of Control and Treatment groups were made by one-way ANOVA followed by Dunnett's post hoc test. *p < 0.05, **p < 0.01 vs. Control n = 4.

FIGURE 9 | The effect of FGY-1153 on the ERK 1/2 signaling in heart of SHR rats. Data are presented as mean ± S.E.M. Data were analyzed by independent samples t-test between WKY and Control groups. Comparisons of Control and Treatment groups were made by one-way ANOVA followed by Dunnett's post hoc test. **p < 0.01, n = 4.
dose treatment had no significant effect on the phosphorylation of MAPKs. Actin is shown as loading control. Representative immunoblots from four experiments and densitometric evaluation are demonstrated (Figure 10).

**Effect of FGY-1153 on the Phosphorylation of Akt/GSK-3β Signaling Cascade in Heart and Great Vessels**

**Western Blot Analysis of Heart Samples**

Western blot analysis showed GSK-3β phosphorylation to be significantly lower in WKY relative to Control group. High dose of FGY-1153 treatment significantly elevated phosphorylation of Akt protein, and both low dose and high dose treatment significantly attenuated the GSK-3β phosphorylation (data not shown).

**Western Blot Analysis of Carotid Samples**

Western blot analysis of Akt protein and GSK-3β phosphorylation showed no difference between the WKY and control SHR groups. FGY-1153 treatment significantly promoted the phosphorylation of Akt protein and GSK-3β in the carotid tissues of both FGY120 and FGY400 groups. However, the high dose treatment had milder effect on the GSK-3β phosphorylation in the FGY400 group. Actin is shown as loading control. Representative immunoblots from four experiments and densitometric evaluation are demonstrated (Figure 11).

**DISCUSSION**

The major finding of this study is that pharmacological inhibition of bradykinin B1 receptors do not cause elevation of blood pressure and do not cause worsening of hypertensive target organ damages in a chronic hypertensive animal model. Moreover, we have found that the administration of FGY-1153, an experimental bradykinin B1 receptor antagonist compound causes slight protective effect against cardiovascular remodeling. We used SHR which provide an animal model of high blood pressure that is similar to essential hypertension in humans (Ito et al., 2007).

Hypertension is a growing public health problem mainly in middle-aged and in elderly people. In hypertensive patients systolic blood pressure (SBP) and pulse pressure are the dominant prognostic markers. Plenty of studies showed that increasing levels of SBP were associated with a higher risk of cerebro- and cardiovascular events. Unfortunately, the rate of hypertension control only minimally improved over the last decades. One important factor in the background of the inadequate hypertension control is the drug interactions between

![FIGURE 10](image-url)
antihypertensive agents and several non-cardiovascular drugs, e.g., NSAIDs (Pavličević et al., 2008; Deedwania, 2011).

Moreover, it is also well-known, that the worldwide commonly prescribed pain relievers, the NSAIDs can significantly increase cardiovascular morbidity and mortality (Patrono and Baigent, 2014). This unfavorable phenomenon is partly caused by the increase in atherothrombotic events (García Rodríguez et al., 2008; McGettigan and Henry, 2011), but the other major cause is the increase in mortality due to heart failure (García Rodríguez and Hernandez-Diaz, 2003).

Because of the above mentioned causes there is an unmet medical need to develop novel and safer anti-inflammatory compounds.

Kinins are biologically active peptides that exert a broad spectrum of physiological effects, including vasodilation, smooth muscle contraction, inflammation, and pain induction (Tschöpe et al., 2000). The biological effects of kinins are mediated through the stimulation of bradykinin B1 and B2 receptors. The B2 receptor is constitutively expressed and is activated by intact kinins, bradykinin, and kallidin. This receptor is believed to play an important role in mediating the beneficial effects of ACE-inhibitors, but it is also involved in the acute phases of inflammation (Tschöpe et al., 2000; Leeb-Lundberg et al., 2005; Golias et al., 2007). However, the B1 receptor is activated by the carboxypeptidase metabolites of kinins, des-Arg9-BK and des-Arg10-kallidin. The B1 receptor is normally weakly expressed, but it is upregulated in the presence of cytokines, endotoxins or during tissue injury (Tschöpe et al., 2000; Leeb-Lundberg et al., 2005; Golias et al., 2007). The B1 receptor mediates chronic inflammation and pain (Leeb-Lundberg et al., 2005; Golias et al., 2007); thus, bradykinin B1 receptor antagonism can be a potential novel approach for treating these conditions without having deleterious cardiovascular effects.

On this basis, we examined the effect of FGY-1153, a bradykinin B1 receptor antagonist (administered in two concentrations) on the cardiovascular changes provoked by chronic hypertension.

FGY-1153 treatment did not have any effects on food consumption and on body weight. The mean daily doses of FGY-1153 in the 120 ppm and 400 ppm groups were approximately 6 mg/kg and 20 mg/kg, respectively.

Chronic onset of elevated blood pressure in hypertension leads to the development of hypertensive cardiopathy (Montezano et al., 2015). This pathology of heart is characterized morphologically by marked thickening of left ventricular walls, also known as left ventricular hypertrophy. Functionally these hearts show diastolic dysfunction and if the hypertension is not treated properly, finally the contractile function will also be

---

**FIGURE 11** | The effect of FGY-1153 on the Akt/GSK-3β signaling cascade in carotis wall. Data are presented as mean ± S.E.M. Data were analyzed by independent samples t-test between WKY and Control groups. Comparisons of Control and Treatment groups on GSK-3β data were made by one-way ANOVA followed by Dunnett’s post hoc test. On Akt data one-way ANOVA with Welch correction were conducted followed by Dunnett T3 post hoc test. *p < 0.05, **p < 0.01 vs. Control, n = 4.
that have an important role in the pathogenesis of vascular and can alter the activity of several signal transduction pathways (PI3K/Akt-1/GSK-3β) (Tanaka et al., 2001). In the recent work hypertension caused an increased phosphorylation state of the various MAPKs (p38-MAPK, ERK, JNK). However, FGY-1153 treatment did not cause consistent and significant changes in the activation state of these signaling molecules. ERK1/2 activity decreased in heart samples and JNK activity was also decreased in carotid arterial samples compared to untreated ones. However, in other samples there were no differences between treated and untreated animals.

In conclusion, the bradykinin B1 receptor antagonist compound FGY-1153 did not have any deleterious effects in SHR rats administering in low dose nor in high dose. Moreover we could observe some protective effects against hypertensive cardiovascular remodeling despite the fact that FGY-1153 did not have any antihypertensive effect. Inhibition of the TGF-β/Smad-2 and activation of Akt-1/GSK-3β signaling may be the main underlying mechanisms in the background of its cardiovascular protective effect.

CONCLUSION

In conclusion, the bradykinin B1 receptor antagonist compound FGY-1153 did not have any deleterious effects in SHR rats administering in low dose nor in high dose. Moreover we could observe some protective effects against hypertensive cardiovascular remodeling despite the fact that FGY-1153 did not have any antihypertensive effect. Inhibition of the TGF-β/Smad-2 and activation of Akt-1/GSK-3β signaling may be the main underlying mechanisms in the background of its cardiovascular protective effect.

DISCLOSURE

CC and SF was employed by company Gedeon Richter Plc., Budapest, Hungary. All other authors declare no competing interests.

ETHICS STATEMENT

The investigation conforms to the Guide for the Care and Use of Laboratory Animals published by the U.S. National Institutes of Health and was approved by the Animal Research Review Committee of the University of Pécs, Medical School (BA02/2000-2/2010).

AUTHOR CONTRIBUTIONS

LD, RH, SF, CC, and KT designed the study. LD, KE, NB, OH, and RH performed the experiments. SF and CC provided compounds.
and rats. LD, RH, TH, KE, and OH processed and analyzed the data. LD, RH, CC, KT, and SF wrote the manuscript. All the authors reviewed and finally approved the manuscript.

**FUNDING**

This work was supported by the New National Excellence Program of the Ministry of Human Capacities, ÚNKP-17-4-I-PTE-209 and by the Hungarian Science Research Fund GINOP-2.3.2-15-2016-00049, GINOP-2.3.2-15-2016-00048, and GINOP-2.3.2-15-2016-00048.

**ACKNOWLEDGMENTS**

We are grateful to Prof. Laszlo Seress for generous contribution to electron microscopic investigations. The manuscript is part of the first author’s Ph.D. thesis.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphys.2019.00624/full#supplementary-material
Pavličević, I., Kuzmanić, M., Rumboldt, M., and Rumboldt, Z. (2008). Interaction between antihypertensives and NSAIDs in primary care: a controlled trial. *Can. J. Clin. Pharmacol.* 15, 372–382.

Perrotta, I., Brunelli, E., Sciangula, A., Conforti, F., Perrotta, E., Tripepi, S., et al. (2011). iNOS induction and PARP-1 activation in human atherosclerotic lesions: an immunohistochemical and ultrastructural approach. *Cardiovasc. Pathol.* 20, 195–203. doi: 10.1016/j.carpath.2010.06.002

Puddu, P., Puddu, G. M., Cravero, E., Rosati, M., and Muscari, A. (2008). The molecular sources of reactive oxygen species in hypertension. *Blood Press.* 17, 70–77. doi: 10.1080/08037050802029954

Ruiz-Ortega, M., Rodríguez-Vita, J., Sanchez-Lopez, E., Carvajal, G., and Egido, J. (2007). TGF-β signaling in vascular fibrosis. *Cardiovasc. Res.* 74, 196–206. doi: 10.1016/j.cardiores.2007.02.008

Sandow, S. L., Gzik, D. J., and Lee, R. M. (2009). Arterial internal elastic lamina holes: relationship to function? *J. Anat.* 214, 258–266. doi: 10.1111/j.1469-7580.2008.01020.x

Sato, E., Koyama, S., Nomura, H., Kubo, K., and Sekiguchi, M. (1996). Bradykinin stimulates alveolar macrophages to release neutrophil, monocyte, and eosinophil chemotactic activity. *J. Immunol.* 157, 3122–3129.

Sharifov, O. F., Schiros, C. G., Aban, I., Denney, T. S., and Gupta, H. (2016). Diagnostic accuracy of tissue doppler index e/e’ for evaluating left ventricular filling pressure and diastolic dysfunction/heart failure with preserved ejection fraction: a systematic review and meta-analysis. *J. Am. Heart Assoc.* 5, e002530. doi: 10.1161/JAHA.115.002530

Tanaka, K., Honda, M., and Takabatake, T. (2001). Redox regulation of MAPK pathways and cardiac hypertrophy in adult rat cardiac myocyte. *J. Am. Coll. Cardiol.* 37, 676–685. doi: 10.1016/s0735-1097(00)01123-2

Tiffany, C. W., and Burch, R. M. (1989). Bradykinin stimulates tumor necrosis factor and interleukin-1 release from macrophages. *FEBS Lett.* 247, 189–192. doi: 10.1016/0014-5793(89)81331-6

Trippodo, N. C., and Frohlich, E. D. (1981). Similarities of genetic (spontaneous) hypertension: man and rat. *Circ. Res.* 48, 309–319. doi: 10.1161/01.res.48.3.309

Tschöpe, C., Heringer-Walther, S., and Walther, T. (2000). Regulation of the kinin receptors after induction of myocardial infarction: a mini-review. *Braz. J. Med. Biol. Res.* 33, 701–708. doi: 10.1590/S0100-879x2000000600011

Westermann, D., Walther, T., Savvatis, K., Escher, F., Sobirey, M., Riad, A., et al. (2009). Gene deletion of the kinin receptor B1 attenuates cardiac inflammation and fibrosis during the development of experimental diabetic cardiomyopathy. *Diabetes* 58, 1373–1381. doi: 10.2337/db08-0329

Yang, S., Li, H., Tang, L., Ge, G., Ma, J., Qiao, Z., et al. (2015). Apelin-13 protects the heart against ischemia-reperfusion injury through the RISK-GSK-3β-mPTP pathway. *Arch. Med. Sci.* 11, 1065–1073. doi: 10.5114/ams.2015.54863

Yin, H., Chao, J., Bader, M., and Chao, L. (2007). Differential role of kinin B1 and B2 receptors in ischemia-induced apoptosis and ventricular remodeling. *Peptides* 28, 1383–1389. doi: 10.1016/j.peptides.2007.05.010

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

*Copyright © 2019 Deres, Eros, Horvath, Cseko, Farkas, Habon, Toth and Halmosi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*